Pure Global AI
NCT05813132Recruiting

BeEAM Versus CEM in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation

BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus CEM (Carboplatin, Etoposide, Melphalan) in Lymphoma Patients as a Conditioning Regimen Before Autologous Hematopoietic Cell Transplantation
Rehab WeridaClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Lymphoma
Drug/Device/Intervention
BEAM Protocol
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Rehab Werida
Funder
Damanhour University
Location
Cairo, Egypt
Timeline & enrollment
Phase
N/A
Start date
Dec 01, 2022
End date
Dec 31, 2023
Enrollment
60 participants
Primary outcome

Incidence of Side Effects.

Summary

The proposed research aims to compare between BeEAM standard regimen and CEM as conditioning
 regimen in lymphoma patients in safety profile& toxicity, infections (Febrile neutropenia)
 during transplant, time to engraftment (recovery not neutropenic), Length of stay at
 hospital, time to relapse, and other complications.

ICD-10 classifications
Hodgkin lymphomaFollicular lymphomaNon-Hodgkin lymphoma, unspecifiedFollicular lymphoma, unspecifiedHodgkin lymphoma, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05813132
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05813132 through Pure Global AI's free database. This phase not specified trial is sponsored by Rehab Werida and is currently Recruiting. The study focuses on Lymphoma. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.